Healthcare / Diagnostics & ResearchParis
$61.86
+0.70 (+1.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $564.1M · quality 72.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.8B
P/E
24.3x
↑EV/EBITDA
9.9x
↓ROE
10.5%
↑Gross Margin
68.1%
↑Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.8%
FCF CAGR
+5.8%
FCF margin
7.7%
FCF / Net income
1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.30B · net income $474.8M · FCF $564.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.30B | $7.30B | $6.95B | $6.51B | $6.71B |
| Net Income | $474.8M | $474.8M | $406.4M | $310.2M | $610.2M |
| EBITDA | $1.53B | $1.53B | $1.40B | $1.22B | $1.49B |
| EPS | 2.55 | 2.55 | 2.09 | 1.57 | 3.07 |
| Gross Margin | 68.1% | 68.1% | 67.8% | 67.0% | 66.8% |
| Operating Margin | 11.2% | 11.2% | 10.4% | 8.4% | 11.7% |
| Net Margin | 6.5% | 6.5% | 5.8% | 4.8% | 9.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 0.68 | 0.77 | 0.70 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $564.1M | $564.1M | $790.5M | $467.8M | $476.1M |
| Returns | |||||
| ROE | 10.5% | 10.5% | 7.6% | 6.1% | 12.8% |
| Valuation | |||||
| P/E | 24.26 | 24.26 | 23.48 | 36.60 | 21.55 |
| EV/EBITDA | 9.89 | 9.89 | 8.98 | 11.57 | 10.71 |
| P/B | 2.54 | 2.54 | 1.79 | 2.24 | 2.75 |
| Growth & Yield | |||||
| Revenue Growth | 5.0% | 5.0% | 6.7% | -2.9% | — |
| EPS Growth | 22.0% | 22.0% | 33.1% | -48.9% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.1%
EPS terminal req.
$5.49
Spread vs growth
-7.1%
5Y implied EPS CAGR
21.1%
EPS terminal req.
$6.64
Spread vs growth
0.9%
10Y implied EPS CAGR
15.4%
EPS terminal req.
$10.70
Spread vs growth
6.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.9%
Start / end P/E
27.5x → 24.5x
EPS bridge
2.09 → 2.55
Residual
-2.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.